Pharmaceutical industry: 2023 in retrospect
European Pharmaceutical Review
JANUARY 29, 2024
During 2023, there were five revisions to the European Medicines Agency ’s (EMA’s) Questions and Answers (Q&As) for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products. These changes are summarised in Table 1.
96 
Let's personalize your content